Rejected at 8:15 p.m. May, 07, 2024 ] by Cameron
Author: beejumm
Related Note: 1514576041266
Rationale for change

Per Amboss:

Patient with no active MAC infection + NOT on cART → Macrolide (azithromycin or clarithromycin)

Patient with no active MAC infection + NOT on fully effective cART (= ineffective cART) → Macrolide (azithromycin or clarithromycin)

Prophylaxis to be stopped with viral load becomes undetectable (i.e., fully suppressive regimen)

Patient on fully effective cART → No prophylaxis to be given

Patient starting cART → No prophylaxis to be given

......

Patient on ineffective cART is given the same management as if they aren't on cART
Only patients on effective cART or about to start cART aren't given anything


Source: AMBOSS - https://next.amboss.com/us/article/1o02aS#Ycd6a18c4baf02c74094511b9797b83a9

Rejection reason

Comments

Text Text
Extra Extra
#AK_Step2_v12::#Subjects::Microbiology::01_Bacteria::08_Mycobacteria::Mycobacterium_Avium_Complex::Prophylaxis #AK_Step1_v12::#B&B::13_Infectious_Disease::06_Viruses::06_HIV #AK_Step1_v12::$AnKingUpdates::$Errata::v11 #AK_Step1_v12::#Physeo::^physeo_image_update #AK_Step1_v12::#FirstAid::03_Microbiology::07_Antimicrobials::27_Antimycobacterial_therapy #AK_Step2_v12::#AMBOSS::IF0Yj3 #AK_Step1_v12::#Bootcamp::Microbiology::36_Antibiotics::23_Rifamycins #AK_Step2_v12::#UWorld::COMLEX::100060 #AK_Step1_v12::#SketchyPharm::07_Antimicrobials::03_Antimycobacterials::02_Leprosy_Drugs::zanki_extra #AK_Original_Decks::Step_1::Zanki_Pharmacology #AK_Step2_v12::#Subjects::Microbiology::01_Bacteria::08_Mycobacteria::Mycobacterium_Avium_Complex #AK_Step2_v12::Original_decks::MedicalArk::im::amboss #AK_Step2_v12::$AnKingUpdates::$Errata::v11 #AK_Step2_v12::#B&B::08_Infectious_Disease::03_HIV::01_HIV_Infection::Extra #AK_Step1_v12::#Bootcamp::Microbiology::35_Opportunistic_Infections::07_Cytomegalovirus,_Disseminated_Mycobacterial_Non-Tuberculous_Disease !AK_UpdateTags::Table::HIV_Opportunistic_Prophylaxis #AK_Step1_v12::#OME::PreClinical::Microbiology::Microbiology_2::Antibacterials::Antimycobacterials #AK_Step1_v12::#Physeo::09_Pharm::05_Antibiotics::22_Dapsone,_Rifamycins,_Clofazimine_(Leprosy_Drugs) #AK_Step2_v12::Original_decks::Dorian::im::ome::infection::hiv #AK_Step2_v12::!Shelf::IM #AK_Step2_v12::!Shelf::IM::no_dupes #AK_Step1_v12::#SketchyMicro::01_Bacteria::08_Mycobacteria::03_Mycobacterium_avium_intracellulare,_Mycobacterium_scrofulaceum,_Mycobacterium_marinum #AK_Step1_v12::^Other::^HighYield::2-RelativelyHighYield #AK_Step1_v12::#Bootcamp::Microbiology::36_Antibiotics::24_Pyrazinamide_Ethambutol_Dapsone_and_Clofazimine #AK_Step1_v12::#FirstAid::03_Microbiology::07_Antimicrobials::26_Antituberculous_drugs::*Rifamycins #AK_Step1_v12::^Other::^FA_Updates::FA2018 #AK_Step2_v12::#B&B::08_Infectious_Disease::03_HIV::03_HIV_Complications::Extra #AK_Step2_v12::#Resources_by_rotation::IM::ome::infection::hiv #AK_Step2_v12::#SketchyIM::09_Infectious_Diseases::Retired_Lessons::04_HIV_&_AIDS::03_AIDS_SOAP_[OLD_VERSION] #AK_Step1_v12::^Other::^EXPN #AK_Step1_v12::#Bootcamp::Microbiology::36_Antibiotics::14_Macrolides #AK_Step2_v12::#UWorld::Step::3252 #AK_Step2_v12::$AnKingUpdates::$Errata::v10-minor_text_changes #AK_Step1_v12::#B&B::13_Infectious_Disease::02_Bacteria::08_Mycobacteria #AK_Step1_v12::#SketchyPharm::07_Antimicrobials::02_Inhibitors_of_Bacterial_Protein_Synthesis::02_Macrolides #AK_Step2_v12::#Resources_by_rotation::IM::amboss_medicalark !AK_UpdateTags::Step1decks::Zanki-Pharmacology #AK_Step1_v12::#Physeo::09_Pharm::05_Antibiotics::16_Macrolides